1789 — ScinoPharm Taiwan Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual cashflow statement for ScinoPharm Taiwan, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	302	438	349	413	147
Depreciation
Amortisation
Non-Cash Items	-35.2	-15	-25.9	-26.4	-7.34
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-139	-88.7	-553	-124	-60.9
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	510	774	231	751	596
Capital Expenditures	-314	-243	-268	-280	-291
Purchase of Fixed Assets
Other Investing Cash Flow Items	244	-10.3	35.1	-13.2	-1,160
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	-70	-254	-233	-293	-1,451
Financing Cash Flow Items	2.35	-1.3	-1.03	2.64	-0.89
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Debt
Cash from Financing Activities	-413	-315	-341	-245	-202
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	26	214	-353	224	-1,056